Cohance lifesciences Limited has announced a significant employee stock option grant, with its Nomination and Remuneration Committee approving the allocation of 1,98,711 stock options to eligible employees under the Employee Stock Option Plan 2023 (ESOP 2023). The decision was made during the committee meeting held on March 13, 2026.

Stock Option Grant Details

The comprehensive stock option grant encompasses several key parameters designed to align employee interests with company performance:

Vesting and Exercise Framework

The stock options operate under a structured timeline designed to promote long-term employee retention:

The Nomination and Remuneration Committee retains discretionary authority to modify vesting schedules, provided such changes do not adversely impact employee interests and comply with applicable laws.

Regulatory Compliance and Documentation

This stock option grant fulfills disclosure requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has structured the ESOP 2023 in accordance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, ensuring full regulatory compliance.

The announcement was signed by Himanshu Agarwal, Whole-time Director and Chief Financial Officer, emphasizing the strategic importance of this employee benefit initiative. Detailed terms and conditions of the stock options are available in the ESOP 2023 document on the company's official website.

Strategic Implications

This stock option grant represents Cohance Lifesciences' commitment to employee engagement and retention through equity participation. The flexible vesting period of 1-10 years allows the company to tailor incentives based on individual employee roles and performance expectations, while the 3-year exercise window provides sufficient time for employees to make informed decisions regarding their equity participation.

Cohance Lifesciences Limited has received a disclosure under SEBI takeover regulations from Jasti Property and Equity Holdings Private Limited, acting as sole trustee of Jasti Family Trust, regarding changes in shareholding patterns. The latest disclosure, dated February 24, 2026, was submitted to both NSE and BSE pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

Latest Transaction Overview

The Jasti Family Trust and its persons acting in concert (PAC) have maintained their combined shareholding in Cohance Lifesciences at 6.36% of the total share capital through internal restructuring. The transaction involved 77,00,000 shares, representing 2.01% of the company's total voting capital, executed through inter-se transfer via block deals on February 23, 2026.

Internal Shareholding Restructuring

While the overall group holding remained unchanged, there was significant internal restructuring among the entities within the Jasti Family Trust group:

Primary Entity Changes

• Jasti Property and Equity Holdings Private Limited (as sole trustee): Reduced from 1,73,16,009 shares (4.53%) to 96,16,009 shares (2.52%)
• Jasub Property Holdings LLP (PAC): Increased from 70,00,000 shares (1.83%) to 1,47,00,000 shares (3.84%)

Other PAC Members

• Mrs. Venkata Subbamma Jasti: 6,000 shares (negligible percentage)
• Mr. Venkateswarlu Jasti: 2,000 shares (negligible percentage)
• Mrs. Sudharani Jasti: 2,000 shares (negligible percentage)

Transaction Details

Company Capital Structure

The company's equity share capital remained unchanged at 38,25,67,140 shares, while the total diluted share capital stands at 39,22,07,995 shares, assuming full conversion of outstanding convertible securities and warrants.

Regulatory Compliance

The disclosure confirms that the acquirer does not belong to the promoter or promoter group of Cohance Lifesciences Limited. The transaction was conducted in compliance with SEBI regulations, with proper notifications submitted to both stock exchanges where the company's shares are listed - BSE Limited and National Stock Exchange of India Limited.

The disclosure was signed by Venkateswarlu Jasti on behalf of Jasti Property and Equity Holdings Private Limited in its capacity as sole trustee of Jasti Family Trust, with copies provided to the company secretary of Cohance Lifesciences Limited.